Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing .
Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements .
Scientists developing chimeric antigen receptor (CAR) T cell products strive to maximize specificity, potency, and persistence of these therapies, but the inability to predict treatment efficacy and response remains a significant challenge. Daniel Hui, PhD, Associate Director of Analytical Development at Tmunity Therapeutics, addresses these challenges and highlights the company’s multiplatform approach to build an innovative “toolbox” of orthogonal assays to provide a comprehensive set of data to characterize CAR-T cell therapeutic products.